Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

B7-33 Nasal Spray

£40.10£75.20

Buy B7-33 Nasal Spray

B7-33 possesses potent anti-fibrotic effects. Reduced fibrosis can help with both chronic and acute conditions such as heart failure, lung inflammation, and kidney inflammation. B7-33 has been proven in animal experiments to reduce fibrosis, resulting in longer survival after injury and treatment for heart failure.

B7-33 15ml – Contains: 4mg

B7-33 30ml – Contains: 8mg

Buy 10 and get 10% Discount

481 in stock

Description

B7-33 Peptide Nasal Spray New Zealand

This product is intended for research purposes only. To be used by trained professionals only.

H2-relaxin, a more significant naturally occurring protein, is the source of B7-33, a soluble single-chain peptide. B7-33 nasal spray keeps relaxin’s anti-fibrotic properties due to it not increasing cAMP.

B7-33 has powerful anti-fibrotic properties [1]. Chronic and acute diseases like heart failure, inflammation of the lungs or the kidneys can all be helped by reducing fibrosis. B7-33 nasal spray has been shown in animal studies to minimise fibrosis resulting in prolonged survival following injury and providing the treatment for heart failure.

In addition, this peptide stimulates ERK1/2 phosphorylation, which promotes MMP2 expression and collagen degradation.

In the event of a cardiac injury, it appears to lessen the amount of scar tissue that forms [2]. Furthermore, the treatment of vascular disorders and preeclampsia of pregnancy have also shown promising results.

Peptides like B7-33 are synthesised from the human H2-relaxin protein.

In addition, relaxin, insulin-like peptide 3, and insulin-like peptide 5 — are all derivatives of the human H2-relaxin protein. Insulin-like peptides, such as these, have affected the cardiovascular, musculoskeletal, and reproductive systems and others.

Four endogenous receptors (RXFP1/2 and RXFP3/4) exist for the relaxin family peptides. However, relaxin proteins are not the only ones that can bind to the receptors of the relaxin system. Several insulin-like peptides, as well as cAMP and orexin, can all stimulate these receptors.

Anti-inflammatory, antioxidant, and wound healing properties have all been demonstrated for agonists. Relaxin was found to be the primary ligand for these receptors after these findings.

New Zealand Researchers have discovered that relaxin dilates blood vessels, stimulates blood vessel growth, and acts as antihypertrophic. Because of its anti-fibrotic properties, relaxin and its derivatives have been the subject of extensive research to treat acute heart failure and other fibrotic diseases.


References:

[1] https://pubs.acs.org/doi/abs/ 10.1021/acsami.9b17859

[2] https://pubmed.ncbi.nlm.nih.gov/ 32295457/


Sequence: VIKLSGRELVRAQIA ISGMSTWSKRSL

B7-33 HPLC 2023 Certificates_DIRECT PEPTIDES

 

 

 

 

 

 

 

 


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our New Zealand Direct Peptides website: https://new-zealand.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.


BUY B7-33 Nasal Spray ONLINE today From New Zealand Direct Peptides

You may also like…